AR127343A1 - Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados - Google Patents

Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados

Info

Publication number
AR127343A1
AR127343A1 ARP220102776A ARP220102776A AR127343A1 AR 127343 A1 AR127343 A1 AR 127343A1 AR P220102776 A ARP220102776 A AR P220102776A AR P220102776 A ARP220102776 A AR P220102776A AR 127343 A1 AR127343 A1 AR 127343A1
Authority
AR
Argentina
Prior art keywords
residue
smm3
smm2
smm1
monomeric
Prior art date
Application number
ARP220102776A
Other languages
English (en)
Inventor
Scolan Erwan Le
Amanda C Kohler
Madan M Paidhungat
Dylan L Daniel
Lauren Kadavy
Original Assignee
Cytomx Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytomx Therapeutics Inc filed Critical Cytomx Therapeutics Inc
Publication of AR127343A1 publication Critical patent/AR127343A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/525—Tumour necrosis factor [TNF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Abstract

La presente invención provee construcciones de citoquinas activables que incluyen: una primera construcción monomérica que comprende una primera proteína citoquina (CP1), un primer resto escindible (CM1), y un primer resto de enmascaramiento estérico (SMM1), en donde el CM1 está ubicado entre la CP1 y el SMM1; una segunda construcción monomérica que comprende una segunda proteína citoquina (CP2), un segundo resto escindible (CM2), y un segundo resto de enmascaramiento estérico (SMM2), en donde el CM2 está ubicado entre la CP2 y el SMM2; y una tercera construcción monomérica que comprende una tercera proteína citoquina (CP3), un tercer resto escindible (CM3), y un tercer resto de enmascaramiento estérico (SMM3), en donde el CM3 está ubicado entre la CP3 y el SMM3, en donde: la CP2, la CP2 y la CP3 se unen entre sí, formando de este modo un trímero de la primera, la segunda y la tercera construcciones monoméricas; y el SMM1, el SMM2, y el SMM3 son moléculas globulares. Reivindicación 4: La ACC de la reivindicación 2, caracterizada porque la CP1, la CP2 y la CP3 son el miembro 14 de la superfamilia del factor de necrosis tumoral (TNFSF14). Reivindicación 45: La ACC de la reivindicación 41 o 42, caracterizada porque la actividad es la activación del mediador de entrada del virus del herpes y la activación del receptor b de linfotoxina. Reivindicación 63: El método de la reivindicación 62, caracterizado porque el sujeto ha sido identificado o diagnosticado como sujeto que tiene cáncer.
ARP220102776A 2021-10-13 2022-10-12 Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados AR127343A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202163255340P 2021-10-13 2021-10-13

Publications (1)

Publication Number Publication Date
AR127343A1 true AR127343A1 (es) 2024-01-31

Family

ID=84362661

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP220102776A AR127343A1 (es) 2021-10-13 2022-10-12 Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados

Country Status (3)

Country Link
AR (1) AR127343A1 (es)
TW (1) TW202334186A (es)
WO (1) WO2023064791A1 (es)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0279862B1 (en) 1986-08-28 1993-11-03 Teijin Limited Cytocidal antibody complex and process for its preparation
ES2091684T3 (es) 1992-11-13 1996-11-01 Idec Pharma Corp Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b.
EP3492488A1 (en) 2007-08-22 2019-06-05 The Regents of The University of California Activatable binding polypeptides and methods of identification and use thereof
CA2753294A1 (en) 2009-02-23 2010-08-26 Cytomx Therapeutics, Inc. Proproteins and methods of use thereof
CN113166220A (zh) * 2018-03-09 2021-07-23 奥美药业有限公司 创新细胞因子前药
BR112020023118A2 (pt) * 2018-05-14 2021-04-13 Werewolf Therapeutics, Inc. Polipeptídeos de interleucina 12 ativáveis e métodos de uso destes
KR20210021467A (ko) * 2018-05-14 2021-02-26 웨어울프 세라퓨틱스, 인크. 활성화가능한 인터루킨-2 폴리펩타이드 및 이의 사용 방법
AU2020384375A1 (en) * 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof

Also Published As

Publication number Publication date
WO2023064791A1 (en) 2023-04-20
TW202334186A (zh) 2023-09-01

Similar Documents

Publication Publication Date Title
PE20191463A1 (es) Anticuerpos biespecificos de union especifica pd1 y lag3
JP2018522055A5 (es)
AR127343A1 (es) Construcciones de citoquinas activables triméricas y composiciones y métodos relacionados
Li et al. Administration of signalling molecules dictates stem cell homing for in situ regeneration
CL2020000252A1 (es) Muteínas de interleucina 21 y métodos de tratamiento.
AR071831A1 (es) Sistemas no invasivos y metodos para fotobiomodulacion in situ. composicion farmaceutica. kit.
AT519084A3 (de) Leuchte
AR086511A2 (es) Agentes de union especifica al factor de crecimiento de hepatocitos
BR112022009110A2 (pt) Polipeptídeos de citocina ativáveis e métodos de uso destes
AR080663A1 (es) Proteinas de union especificas y sus usos
EP2911684A2 (en) Il-15r alpha forms, cells expressing il-15r alpha forms, and therapeutic uses of il-15r alpha and il-15/il-15r alpha complexes
ATE444969T1 (de) Dimerisiertes peptid
MX2017001273A (es) Iluminacion trasera de vehiculo.
PE20240123A1 (es) Mutante de il-2 y aplicacion de este
BR112022023288A2 (pt) Polipeptídeos de il-12 ativáveis e métodos de uso dos mesmos
Hong et al. Self-assembling injectable peptide hydrogels for emerging treatment of ischemic stroke
WO2021181233A3 (en) Cd80-fc fusion protein and uses thereof
US20220110971A1 (en) T Cell Modulator
EP3973955A3 (en) Particle-mediated delivery of inhibitory rna
AU2020272055A1 (en) IR700 nanocompositions for cardiac therapies and applications
AR127275A1 (es) Construcciones de citoquinas activables y composiciones y métodos relacionados
AR108681A1 (es) Proteínas de fusión para oftalmología con retención ocular aumentada
US20170112881A1 (en) Method of Treating Endometriosis
Nguyen et al. Targeted laser irradiation induces immunologic markers of breast cancer cell death
Zlatnik et al. The role of immunological memory in establishing antitumor immunity in patients with ovarian cancer undergoing neoadjuvant therapy